Lung adenocarcinoma — guidelines¶
TL;DR — Lung adenocarcinoma is governed by NSCLC, pathology, molecular-testing, screening, radiation, brain-metastasis, and toxicity guidelines rather than one histology-only document. Their common decision chain is stable: confirm diagnosis and stage, preserve tissue, complete broad molecular and PD-L1 testing before first systemic therapy, use curative local/multimodality treatment when feasible, and select metastatic therapy by actionable driver before PD-L1 (Lindeman 2018, PMID 29398453; ASCO driver-alteration living guideline 2026.3.3, PMID 42607282). Apparent disagreements often reflect jurisdiction, approval date, evidence cutoff, TNM edition, assay, or update cadence rather than conflicting biology. Screening rules genuinely diverge: the 2021 USPSTF uses age 50–80, ≥20 pack-years, and a 15-year quit limit, while the 2023 American Cancer Society update removed quit-years as an eligibility cutoff (USPSTF 2021, PMID 33687470; Wolf 2024, PMID 37909877). A version number, access date, jurisdiction, and actual T/N/M descriptors must travel with every recommendation.
Safe-reading fields¶
| Field | Why it matters | Error prevented |
|---|---|---|
| Issuer/jurisdiction | Approval, reimbursement, and service assumptions differ | Importing an unavailable regimen |
| Version/access date | Living guidelines change within a publication year | Treating an obsolete algorithm as current |
| Evidence cutoff | Omission may mean timing, not negative evidence | False inference from silence |
| TNM edition | Stage labels migrate | Applying an old stage recommendation to new anatomy |
| Histology | Pemetrexed and some bleeding constraints are histology-sensitive | Using a generic NSCLC list |
| Biomarker assay/cutoff | TPS, immune-cell scores, NGS definitions differ | Moving thresholds between assays |
| Recommendation strength | “Offer,” “consider,” and consensus differ | Turning preference-sensitive care into a mandate |
| Trial exclusions | ECOG ≥2, autoimmune, transplant, untreated CNS disease underrepresented | Overstating transportability |
Core guideline set¶
| Body | Region | Scope | Current source used | Key adenocarcinoma contribution |
|---|---|---|---|---|
| ASCO | US/international | Stage IV NSCLC without driver alterations | Living guideline 2026.3.1 (PMID 42190141) | PD-L1- and histology-stratified systemic therapy |
| ASCO | US/international | NSCLC with driver alterations | Living guideline 2026.3.3 (PMID 42607282) | Exact-driver sequencing and resistance |
| ASCO | US/international | Stage III NSCLC | 2022 guideline (PMID 34936470) | Resectability, chemoradiation, consolidation |
| CAP/IASLC/AMP | International | Molecular testing | 2018 update (PMID 29398453) | Specimen, assay, EGFR/ALK/ROS1 and multiplex principles |
| CAP/AMP/IASLC/PPS/LUNGevity | International | PD-L1/TMB | 2024 guideline (PMID 38625026) | Validated PD-L1; do not use TMB alone |
| NICE | England/Wales | Diagnosis through supportive care | NG122 living web source | Open pathway, MDT, staging, treatment and support |
| ESMO | Europe | Early/local and metastatic NSCLC | Living web guidance | European approvals and evidence grading |
| NCCN | United States | Full NSCLC pathway | Authenticated professional source | Rapid drug/biomarker updates; version must be checked |
| USPSTF | United States | Screening | 2021 statement (PMID 33687470) | Annual LDCT eligibility |
| ACS | United States | Screening | 2023 update (PMID 37909877) | Removes quit-year exclusion |
Screening and referral¶
USPSTF recommends annual LDCT for adults aged 50–80 with at least 20 pack-years who currently smoke or quit within 15 years, stopping when health limits curative treatment (PMID 33687470). ACS uses the same age and pack-year thresholds but does not exclude former smokers solely by time since quitting (PMID 37909877).
| Issue | Consensus | Divergence/gap |
|---|---|---|
| Test | LDCT, not chest radiography | Nodule algorithms and intervals vary |
| Population | Asymptomatic people able/willing to undergo work-up | Age, pack-years, and quit-years vary by policy |
| Tobacco care | Integrate cessation | Delivery model and performance measures vary |
| Never-smokers | No randomized mortality-proven broad program | Risk-enriched Asian cohorts create policy pressure (PMID 38042167) |
| Symptoms | Diagnostic pathway, not screening | Referral thresholds vary by health system |
NLST and NELSON establish mortality efficacy but do not decide national eligibility or implementation capacity (PMIDs: 21714641, 31995683).
Pathology and molecular testing¶
Guidelines converge on obtaining the safest specimen that establishes diagnosis and stage while preserving material. Reflex broad testing reduces loss between pathology sign-out and oncology ordering (CAP/IASLC/AMP, PMID 29398453; reflex implementation study, PMID 32600793).
Contemporary adenocarcinoma testing should resolve EGFR, ALK, ROS1, BRAF, KRAS, MET exon-14, RET, NTRK, and ERBB2/HER2, with PD-L1 reported separately. The 2018 guideline is a methods foundation, not a ceiling on later targets.
| Guardrail | Requirement |
|---|---|
| Plasma | Positive actionable result can be useful; negative requires tissue fallback |
| Fusions | RNA capability when DNA is negative/equivocal or introns are problematic |
| PD-L1 | Name clone/platform, score type, percentage, specimen, adequacy |
| TMB | Do not use alone to select checkpoint therapy (PMID 38625026) |
| Small biopsy | Minimize lineage IHC and serial single-gene depletion |
| Turnaround | Track from specimen acquisition to complete actionable result |
Staging and local therapy¶
Ninth-edition TNM is the current staging frame; it revises N2 and M1c subdivisions and stage groups (Rami-Porta 2024, PMID 38447919; Detterbeck 2024, PMID 38885896). Older guidelines may use seventh or eighth edition. Store descriptors rather than only a stage label.
| Clinical state | Guideline-level default | Qualification |
|---|---|---|
| Operable stage I | Anatomic resection plus nodal evaluation | Selected ≤2-cm peripheral tumors may meet sublobar trial criteria (PMIDs: 35461558, 36780674) |
| Medically inoperable stage I | SABR | Central/ultracentral location and ILD alter risk (PMID 28596092) |
| Resectable stage II–III | Multimodality therapy | Resectability, driver status, and ability to complete surgery |
| Unresectable stage III | Concurrent chemoradiation then consolidation if eligible | Sequential treatment when concurrent therapy unsafe |
| Oligometastatic | Consider definitive local therapy to all sites | Carefully selected, technically treatable disease (PMID 37294262) |
Physiologic operability uses lung function, predicted postoperative reserve, exercise capacity, and cardiac risk rather than age alone (Brunelli 2009, PMID 19477657).
Resected and perioperative disease¶
Cisplatin-based adjuvant chemotherapy has a 5.4% absolute five-year survival benefit in pooled NSCLC data, concentrated in stage II–III (Pignon 2008, PMID 18506026).
Genotype-specific guidance now includes three years of adjuvant osimertinib for eligible classical EGFR-mutant disease and two years of adjuvant alectinib for eligible ALK-positive disease (ADAURA PMIDs: 32955177, 37272535; ALINA PMID 38598794).
Driver-negative perioperative choices include:
| Architecture | Evidence | Unresolved guideline issue |
|---|---|---|
| Neoadjuvant chemo-nivolumab only | CheckMate 816 (PMID 35403841) | Who needs postoperative treatment after non-pCR |
| Perioperative pembrolizumab | KEYNOTE-671 (PMID 37272513) | Marginal value of adjuvant component |
| Perioperative durvalumab | AEGEAN (PMID 37870974) | Cross-trial biomarker and stage differences |
| Perioperative nivolumab | CheckMate 77T (PMID 38749033) | Optimal total duration |
| Adjuvant atezolizumab | IMpower010 (PMID 34555333) | PD-L1 threshold, prior therapy, jurisdiction |
| Adjuvant pembrolizumab | KEYNOTE-091 (PMID 36108662) | Discordant PD-L1 subgroup pattern |
Do not combine trial regimens into an untested sequence. In particular, neoadjuvant checkpoint therapy followed by adjuvant targeted therapy may be clinically considered in exceptional circumstances but requires safety and evidence review.
Unresectable stage III¶
ASCO supports concurrent platinum chemoradiation for fit patients and consolidation durvalumab after definitive therapy without progression (Daly 2022, PMID 34936470). PACIFIC reported durable five-year OS 42.9% versus 33.4% and PFS 33.1% versus 19.0% (Antonia 2017, PMID 28885881; Spigel 2022, PMID 35108059).
EGFR-mutant stage III requires genotype-specific update checking because immunotherapy benefit and targeted consolidation evidence differ from the unselected PACIFIC framework.
Metastatic disease¶
Guideline order matters:
- Complete actionable-driver testing.
- If a validated driver is present, use the matched first-line pathway.
- If driver-negative, interpret PD-L1 with disease tempo and fitness.
- Use nonsquamous chemotherapy backbones; pemetrexed has histology-specific benefit (PMID 21119545).
- At progression, reclassify anatomy and biology; do not follow a fixed drug ladder blindly.
KEYNOTE-189 supports pembrolizumab plus platinum-pemetrexed across PD-L1 strata (PMID 29658856). KEYNOTE-024 supports pembrolizumab monotherapy for selected PD-L1 TPS ≥50%, EGFR/ALK-negative disease (PMID 27718847). Driver-specific randomized evidence can supersede immune-first logic even when PD-L1 is high, as LIBRETTO-431 demonstrates for RET fusions (PMID 37870973).
CNS, supportive care, and emergencies¶
ASCO/SNO/ASTRO recommends local therapy for symptomatic brain metastases regardless of systemic therapy (Vogelbaum 2022, PMID 34932393). CNS-active TKIs can permit deferral in selected asymptomatic disease, but this is driver-, drug-, and lesion-specific.
Early palliative care improves quality of life and mood and reduced aggressive end-of-life care in metastatic NSCLC (Temel 2010, PMID 20818875). Guidelines also cover pleural effusion, thrombosis, febrile neutropenia, and immune adverse events; see red flags and safety concerns.
Genuine disagreements and version hazards¶
| Topic | Difference | Safe resolution |
|---|---|---|
| Screening quit-years | USPSTF ≤15 years; ACS no quit-year cutoff | Apply governing program and document rule |
| TNM edition | Older guideline stage groups versus TNM-9 | Map actual T/N/M descriptors |
| Perioperative IO | Neoadjuvant-only and perioperative regimens coexist | Do not compare HRs or invent combined sequence |
| Adjuvant IO | PD-L1 effects differ between trials | Use exact indication, assay, stage, and prior therapy |
| Molecular scope | 2018 testing guideline predates modern targets | Combine methods guidance with current treatment updates |
| Access | NCCN/ESMO/NICE/ASCO drug lists differ | Separate evidence, authorization, reimbursement |
| TMB | Research signal versus “not alone” guideline | Keep contextual, not decisive |
Guideline audit checklist¶
- [ ] Issuer, jurisdiction, version, and access date recorded.
- [ ] TNM descriptors and edition documented.
- [ ] Histology and differential diagnosis confirmed.
- [ ] Molecular and PD-L1 assays named with specimen date/site.
- [ ] Recommendation strength and evidence certainty preserved.
- [ ] Approval and reimbursement checked locally.
- [ ] Trial eligibility compared with performance status/comorbidity.
- [ ] Multidisciplinary decision and patient preference documented.
- [ ] Emergency and toxicity safety net specified.
Open questions¶
- Can living guidelines publish machine-readable change logs without losing qualifying text?
- How should guidelines prioritize testing in low-resource settings without creating a two-tier standard?
- Which perioperative architecture has the best net benefit, and what is the independent adjuvant contribution?
- When should ctDNA/MRD enter recommendation-grade escalation or de-escalation?
- How should never-smoker screening evidence be generated without unacceptable overdiagnosis?
Related pages¶
- Screening and early detection — eligibility and harms.
- Molecular testing — assay workflow.
- Early-stage and perioperative therapy — resectable disease evidence.
- Systemic therapy — integrated algorithms.
- Clinical trials landscape — evidence likely to change guidance.
References¶
- Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
- Sholl LM, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation. Arch Pathol Lab Med. 2024. PMID 38625026
- Daly ME, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022. PMID 34936470
- US Preventive Services Task Force, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021. PMID 33687470
- Wolf AMD, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024. PMID 37909877
- National Lung Screening Trial Research Team, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011. PMID 21714641
- de Koning HJ, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020. PMID 31995683
- Chang GC, et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir Med. 2024. PMID 38042167
- Rami-Porta R, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024. PMID 38447919
- Detterbeck FC, et al. The Proposed Ninth Edition TNM Classification of Lung Cancer. Chest. 2024. PMID 38885896
- Videtic GMM, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017. PMID 28596092
- Iyengar P, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023. PMID 37294262
- Brunelli A, et al. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009. PMID 19477657
- Pignon JP, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008. PMID 18506026
- Wu YL, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32955177
- Tsuboi M, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023. PMID 37272535
- Wu YL, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024. PMID 38598794
- Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022. PMID 35403841
- Wakelee H, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023. PMID 37272513
- Heymach JV, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023. PMID 37870974
- Antonia SJ, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017. PMID 28885881
- Spigel DR, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID 35108059
- Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018. PMID 29658856
- Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016. PMID 27718847
- Vogelbaum MA, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022. PMID 34932393
- Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010. PMID 20818875
- Reuss JE, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.1. J Clin Oncol. 2026. PMID 42190143
- Wheatley Price P, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3. J Clin Oncol. 2026. PMID 42607282
- Bazhenova L, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.1. J Clin Oncol. 2026. PMID 42190141
- Anand K, et al. Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. Clin Lung Cancer. 2020. PMID 32600793
- Scagliotti G, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011. PMID 21119545
- Cascone T, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024. PMID 38749033
- Felip E, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021. PMID 34555333
- O'Brien M, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022. PMID 36108662
- Zhou C, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023. PMID 37870973